We are live on ! Find out more
NVS icon

Novartis

877 hedge funds and large institutions have $18.7B invested in Novartis in 2016 Q3 according to their latest regulatory filings, with 53 funds opening new positions, 323 increasing their positions, 339 reducing their positions, and 43 closing their positions.

New
Increased
Maintained
Reduced
Closed

23% more first-time investments, than exits

New positions opened: 53 | Existing positions closed: 43

11% more call options, than puts

Call options by funds: $50M | Put options by funds: $45M

0.01% less ownership

Funds ownership: 10.04%10.03% (-0.01%)

0% less funds holding

Funds holding: 878877 (-1)

4% less capital invested

Capital invested by funds: $19.5B → $18.7B (-$835M)

5% less repeat investments, than reductions

Existing positions increased: 323 | Existing positions reduced: 339

24% less funds holding in top 10

Funds holding in top 10: 3728 (-9)

Holders
877
Holders Change
-1
Holders Change %
-0.11%
% of All Funds
23.4%
Holding in Top 10
28
Holding in Top 10 Change
-9
Holding in Top 10 Change %
-24.32%
% of All Funds
0.75%
New
53
Increased
323
Reduced
339
Closed
43
Calls
$50M
Puts
$45M
Net Calls
+$5M
Net Calls Change
+$2.72M
Name Holding Trade Value Shares
Change
Change in
Stake
Dodge & Cox
1
Dodge & Cox
California
$3.44B -$63.8M -875,641 -2%
Primecap Management
2
Primecap Management
California
$1.62B -$22.3M -305,868 -1%
Franklin Resources
3
Franklin Resources
California
$1B +$55.9M +767,041 +6%
BBHC
4
Brown Brothers Harriman & Co
New York
$744M -$21.8M -299,817 -3%
Wells Fargo
5
Wells Fargo
California
$592M +$574K +7,878 +0.1%
Bank of America
6
Bank of America
North Carolina
$500M +$17.5M +239,812 +4%
Fisher Asset Management
7
Fisher Asset Management
Washington
$479M -$24.3M -333,116 -5%
Loomis, Sayles & Company
8
Loomis, Sayles & Company
Massachusetts
$462M +$20.3M +278,138 +4%
UBS Group
9
UBS Group
Switzerland
$438M +$9.45M +129,663 +2%
Parnassus Investments
10
Parnassus Investments
California
$338M +$64.7M +888,458 +23%
Manulife (Manufacturers Life Insurance)
11
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$305M -$8.8M -120,749 -3%
Mawer Investment Management
12
Mawer Investment Management
Alberta, Canada
$304M +$8.9M +122,125 +3%
MNA
13
Manning & Napier Advisors
New York
$296M +$15.2M +209,192 +5%
Northern Trust
14
Northern Trust
Illinois
$270M -$7.21M -98,959 -3%
State Street
15
State Street
Massachusetts
$245M -$5.58M -76,524 -2%
T
16
Thomaspartners
Massachusetts
$219M +$12.6M +172,531 +6%
Aristotle Capital Management
17
Aristotle Capital Management
California
$214M -$1.69M -23,242 -0.8%
Renaissance Technologies
18
Renaissance Technologies
New York
$199M +$20.7M +284,022 +11%
Lazard Asset Management
19
Lazard Asset Management
New York
$186M +$7.13M +97,888 +4%
Capital Research Global Investors
20
Capital Research Global Investors
California
$178M
CI
21
Cambiar Investors
Colorado
$176M +$9.1M +124,943 +5%
Invesco
22
Invesco
Georgia
$162M -$3.44M -47,170 -2%
ClearBridge Investments
23
ClearBridge Investments
New York
$154M -$2.91M -39,922 -2%
Capital World Investors
24
Capital World Investors
California
$153M +$8.21M +112,624 +6%
Morgan Stanley
25
Morgan Stanley
New York
$145M +$4.72M +64,749 +3%

NVS Hedge Fund Activity: Q3 2016 in Review

877 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q3 2016, worth a combined $18.7B — down 4.3% from $19.5B a quarter earlier.

Buyers outnumbered sellers: 53 funds opened new NVS positions and 43 closed out — a net gain of 10 holders — while 323 added to existing stakes and 339 trimmed.

The largest buyer was Parnassus Investments, adding an estimated $64.7M. The largest seller was Macquarie Group, cutting an estimated $125M.

  • 877 institutional investors held Novartis (NVS) as of Q3 2016, down from 878 in Q2 2016.
  • Funds reported $18.7B of Novartis stock for Q3 2016, down 4.3% quarter-over-quarter.
  • 53 funds opened new Novartis positions in Q3 2016 and 43 closed out, a net change of +10 holders.
  • The largest Novartis buyer in Q3 2016 was Parnassus Investments, an estimated $64.7M added.
  • The largest Novartis seller in Q3 2016 was Macquarie Group, an estimated $125M sold.

Based on aggregated 13F filings for Q3 2016.